{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:29:23Z","timestamp":1793755763019,"version":"4.6.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":164,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2026.100598","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:35:56Z","timestamp":1781537756000},"page":"100598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synchronous presentation of pH+ B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia treated with blinatumomab"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2131-5135","authenticated-orcid":false,"given":"Christina","family":"Darwish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don A.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Abdelmessieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2026.100598_bib0001","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","article-title":"Acute lymphocytic leukaemia","volume":"406","author":"Kantarjian","year":"2025","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.lrr.2026.100598_bib0002","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the Dasatinib-Blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lrr.2026.100598_bib0003","first-page":"199","article-title":"Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin\u2019s lymphoma: a systemic review and meta-analysis","volume":"24","author":"Yu","year":"2019","journal-title":"Hematol. (United Kingdom)"},{"key":"10.1016\/j.lrr.2026.100598_bib0004","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41375-022-01649-3","article-title":"A phase two study of high dose blinatumomab in Richter\u2019s syndrome","volume":"36","author":"Thompson","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2026.100598_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-51264-2","article-title":"Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial","volume":"15","author":"Gui\u00e8ze","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lrr.2026.100598_bib0006","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00277-016-2869-6","article-title":"Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis","volume":"96","author":"Zhang","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.lrr.2026.100598_bib0007","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct Blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lrr.2026.100598_bib0008","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic lymphocytic Leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lrr.2026.100598_bib0009","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.lrr.2026.100598_bib0010","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2016-05-714162","article-title":"Minimal residual disease is an independent predictor for 10-year survival in CLL","volume":"128","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2026.100598_bib0011","article-title":"T cells in chronic lymphocytic leukemia: a two-edged sword","volume":"11","author":"Vlachonikola","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lrr.2026.100598_bib0012","article-title":"PD-1 inhibition enhances blinatumomab response in a UCB\/PDX model of relapsed pediatric B-cell acute lymphoblastic leukemia., front","volume":"11","author":"Wunderlich","year":"2021","journal-title":"Oncol"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:11:06Z","timestamp":1793754666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048926000385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":12,"alternative-id":["S2213048926000385"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100598","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synchronous presentation of pH+ B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia treated with blinatumomab","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100598"}}